心泰醫療(02291.HK)發佈盈喜:預計上半年純利同比增長約200%
格隆匯7月7日丨心泰醫療(02291.HK)公佈,根據對集團截至2023年6月30日止六個月的初步未經審計綜合管理賬目的審閲,集團預期將錄得股東應占純利約人民幣7300萬元,較去年同期增加約200%。估計非國際財務報吿準則利潤約為人民幣8500萬元。
股東應占純利的預期增加主要是由於以下原因:(1)集團於報吿期的新一代鎳鈦合金封堵器產品銷量較去年同期大幅增加。此增長乃由於在集團廣泛經銷商網絡、有效學術推廣及強大營銷能力之推動下,該等產品之市場接受度有所提高;及(2)集團於MemoSorb®全降解封堵器系統(由高分子材料製成)商業化後開始銷售此產品,較去年同期而言,其為集團於報吿期內之額外收入來源。
在2023年下半年,公司將進一步提升金屬封堵器的升級換代和可降解封堵器的大範圍推廣。公司相信,集團會維持和擴大其強勁的業務表現,爭取2023年全年為股東帶來更好回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.